NCT00588120View on ClinicalTrials.gov

Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria

PHASE1CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

December 31, 1998

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions
Enteric HyperoxaluriaHyperoxaluria
Interventions
DRUG

C-13 labeled oxalate

"A single prescribed dose of C-13 labeled oxalate will be given orally in capsule form or in jello. Urine will be collected for 24 hours after the dose.~Take one capsule by mouth for one day."

Trial Locations (1)

55905

Mayo Clinic Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

Oxalosis and Hyperoxaluria Foundation (OHF)

OTHER

lead

Mayo Clinic

OTHER